TALK KEYWORD INDEX
This page contains an index consisting of author-provided keywords.
| 1 | |
| 1. HLA-DPB1 | |
| 1. PK -Punjabi Khatri | |
| 1000 genomes project | |
| 12/12 HLA | |
| 2 | |
| 2. KB-Kashmiri Brahmins | |
| 2. T-cell Epitope | |
| 3 | |
| 3' UTR | |
| 3. HLA-DP expression | |
| 3. SCARS- Severe cutaneous acute drug reactions | |
| 4 | |
| 4-field resolution | |
| 4. Graft-versus-Host Disease | |
| 4th field resolution | |
| 5 | |
| 5' UTR | |
| 9 | |
| 9/10 unrelated hematopoietic cell transplantation | |
| A | |
| A*11:01:01:01 | |
| Abacavir | |
| ABMR | |
| Acceptable mismatch program | |
| Accurate HLA typing | |
| ACE1 | |
| activating KIR receptors | |
| acute graft-versus-host disease | |
| Acute Myeloid Leukaemia | |
| acute myeloid leukemia | |
| acute rejection | |
| ADCC | |
| Address | |
| Adoptive cell therapy | |
| Adoptive immunotherapy | |
| Adult Patients | |
| Affinity | |
| Africa | |
| Age | |
| allele | |
| allele frequencies | |
| allele frequency | |
| Allele imputation | |
| alleles | |
| allelic diversity | |
| allelic typing | |
| allo-HSCT | |
| Allocation | |
| allogeneic | |
| allogeneic hematopoietic cell transplantation | |
| allogeneic hematopoietic stem cell transplantation | |
| Allogeneic stem cell transplantation | |
| Allograft Failure | |
| alloimmune response | |
| alloimmunization | |
| allopeptides | |
| Alloreactivity | |
| ALS | |
| Alternative splicing | |
| amino acid substitutions | |
| AML | |
| Analysis | |
| Anthony Nolan | |
| Anthropology | |
| anti HLA antibodies | |
| anti-HLA | |
| anti-HLA alloantibodies | |
| anti-HLA antibodies | |
| Anti-HLA antibody | |
| Anti-HMGCR | |
| anti-inflammatory cytokines | |
| anti-SARS-CoV-2 antibody | |
| anti-SARS-CoV-2 vaccination | |
| Anti-TNF drugs | |
| Antibodies | |
| Antibodies against SARS-CoV-2 | |
| Antibody | |
| antibody affinity | |
| antibody concentration | |
| antibody verification | |
| Antibody Verified-Eplet Mismatch | |
| Antibody-dependent cellular cytotoxicity | |
| Antibody-mediated rejection | |
| antigen binding sites | |
| Antigen presentation | |
| antigens | |
| antitumoral surveillance | |
| APRIL | |
| Armenian population | |
| Ashkenazi | |
| Asia | |
| assay | |
| association | |
| Association studies | |
| association study | |
| autoencoder (AE) | |
| autoimmune | |
| autoimmune comorbidities | |
| autoimmunity | |
| autologous metastases | |
| Automation | |
| Avacavir binding capacity | |
| Award | |
| Awards | |
| B | |
| B cells | |
| B*52:01:01:02 | |
| B-cell | |
| BAFF system | |
| Balancing selection | |
| Barcoded adapters | |
| Barcoded primers | |
| Be The Match Mexico | |
| Best | |
| Best Abstracts | |
| Big data | |
| binding analysis | |
| Binding repertoire | |
| biobank | |
| BIOETHICS | |
| bioinformatic tools | |
| Bioinformatics | |
| Biomarker | |
| bladder cancer | |
| bladder tumor | |
| blasts | |
| blood chimerism | |
| blood group | |
| BMI | |
| Bodmer | |
| bone marrow donors | |
| brain-homing | |
| Brazilian population | |
| Breakthrough infections | |
| breast cancer | |
| BSG | |
| Buccal swab | |
| Bulgarians | |
| Bw4 | |
| C | |
| C*12:02:02:01 | |
| C3d assay | |
| cancer | |
| CAR-T cells | |
| Cardiac allograft vasculopathy | |
| CD147 | |
| CD16 | |
| CD226 | |
| CD4+ T cell immunity | |
| CD4-T cells | |
| CD8 T cells | |
| CD8+ T lymphocytes | |
| CD8-T cells | |
| CDC | |
| CDR3 | |
| celiac disease | |
| Cell atlas | |
| Cell Culture | |
| Cell lines | |
| Cell therapy | |
| cell-free circulating DNA | |
| cellular therapy | |
| Ceppellini | |
| cfDNA | |
| Childhood acute leukemia | |
| Chimeric antigen receptor | |
| Chimeric HLA Antigen Receptor T cells | |
| chimerism | |
| Chimerism analysis | |
| Chimerism monitoring | |
| chimerism testing | |
| Chimpanzees | |
| Chromosome 19 | |
| Chronic hepatitis B | |
| Chronic Intervillositis of Unknown Etiology | |
| Chronic lymphocytic leukemia | |
| Chronic organ rejection | |
| chronic rejection | |
| circulating DSA | |
| Circulating T follicular helper cells | |
| class I new alleles | |
| Class I non-classical HLA genes | |
| Class I non-HLA genes | |
| Class Ib typing | |
| Clinical | |
| clinical outcome | |
| CLL | |
| Closing | |
| Cloud | |
| CMV matching | |
| coevolution | |
| Colorectal cancer | |
| Colton | |
| Common and Well Documented Allele | |
| Comparative primate genetics | |
| Complement component 4 | |
| Computational biology | |
| Convalescent plasma | |
| Copy number | |
| core" alleles | |
| Corona | |
| cost-effective | |
| COVID 19 | |
| COVID-19 | |
| COVID-19 convalescent plasma donors | |
| COVID-19 severity | |
| COVID-19 vaccination | |
| COVID19 | |
| CRISPR Cas13 | |
| crossing over | |
| Crossmatch | |
| Crossmatching | |
| culturing | |
| cutoff | |
| Cytokine | |
| cytokine storm | |
| Cytokines | |
| cytomegalovirus | |
| Cytomegalovirus (CMV) | |
| cytotoxicity | |
| Czechia | |
| D | |
| Data analysis | |
| Data visualization | |
| Database | |
| dd-cfDNA | |
| ddPCR | |
| De novo DSA | |
| DEAV/GGPM polymorphism | |
| Deceased Donor Typing | |
| deep learning | |
| Deletion | |
| Denatured HLA | |
| desensitization | |
| Diego | |
| differentiation | |
| Digital PCR | |
| diploid genotype phasing | |
| disease association | |
| disease severity | |
| Diversity | |
| dizygotic twin couples | |
| DLBCL | |
| DNA | |
| Donor rs2204985 | |
| donor search | |
| Donor selection | |
| donor-specific antibodies | |
| Donor-specific HLA antibodies | |
| donors | |
| DPB1 | |
| DR-panreactivity | |
| droplet digital PCR | |
| Drug metabolism | |
| DSA | |
| DSA - Donor Specific Antibody | |
| DSA-Donor Specific Antibodies | |
| Duffy | |
| E | |
| Easy Sep | |
| EBV-specific T cell | |
| EDTA treatment | |
| EFI | |
| Eiptope Analysis | |
| ELISPOT | |
| elucidate asterisks in CDS sequences | |
| EM-algorithm | |
| EMMA | |
| endothelial antigens | |
| Endothelial permeability | |
| Enrichment | |
| Epitope | |
| epitope specificity | |
| epitope-matching | |
| Epitopes | |
| Eplet | |
| eplet mismatch | |
| Eplet Verification | |
| Eplets | |
| Epstein-Barr virus | |
| EPT | |
| EQA | |
| Equality | |
| evaluation methods | |
| Event Free Survival | |
| Evolution | |
| Evolutionairy stability | |
| Ex vivo Kidney Perfusion | |
| Expansion | |
| expectation-maximization algorithm | |
| expression | |
| Expression levels | |
| extended MHC haplotypes | |
| External proficiency testing | |
| External quality assessment | |
| Extracorporeal photopheresis | |
| Extraction | |
| Ezer Mizion Registry | |
| F | |
| FAIR principles | |
| Families | |
| fast | |
| FCGR3A | |
| FCXM | |
| Fibrobrast associated protein (FAP) expression | |
| Flow Cytometry | |
| Flow cytometry crossmatch | |
| FRENCH LEGAL FRAMEWORK | |
| FREQUENCIES | |
| frequency | |
| Friends To Marrow | |
| full length sequencing | |
| Full-gene sequencing | |
| Fulllength genomic DNA analysis | |
| Functional diversity | |
| G | |
| Gamma-delta T cell | |
| gendx | |
| Gene copy number | |
| gene duplication | |
| gene expression | |
| Gene linkage disequilibrium | |
| genes | |
| Genetic Distance | |
| Genetic diversity | |
| genetic polymorphism | |
| Genetic polymorphisms | |
| Genetic risk | |
| Genetics | |
| genome reference | |
| Genome SNP | |
| Genome-wide mismatch | |
| GENOMIC MEDICINE | |
| Genomic sequencing | |
| Genomics | |
| Genotype | |
| Genotypes | |
| Genotyping | |
| Geographic distances | |
| Gerbich | |
| Global analysis | |
| graft failure | |
| Graft rejection | |
| Graft survival | |
| graft-versus-host | |
| graft-versus-host disease | |
| graft-versus-leukemia | |
| GRIMM | |
| Gut | |
| GVHD | |
| H | |
| haaematopietic | |
| Haematopoietic stem cell transplant | |
| Haematopoietic Stem Cell Transplantation | |
| haplo-HSCT | |
| haploidentical donor | |
| haploidentical hematopoietic stem cell transplantation | |
| Haploidentical HSCT | |
| haploidentical stem cell transplantation | |
| Haplotype | |
| Haplotype frequencies | |
| haplotype frequency | |
| haplotype loss | |
| Haplotypes | |
| HCV | |
| healthy ageing | |
| heart transplantation | |
| heart valvular prosthesis | |
| Hematological malignancies | |
| Hematopoeitic Stem Cell Transplantation | |
| hematopoietic cell transplantation | |
| Hematopoietic stem cell tranplantation | |
| hematopoietic stem cell transplantation | |
| Hematopoietic stem cells | |
| hematopoietic-specific TCRs | |
| herpesviruses | |
| HIBAG | |
| High dimensional flow cytometry | |
| High resolution | |
| high-resolution | |
| Highly Sensitized Candidates | |
| histocompatibility | |
| HLA | |
| HLA allele | |
| HLA allele distribution | |
| HLA alleles | |
| HLA antibodies | |
| HLA antigens | |
| HLA association study | |
| HLA class I | |
| HLA class I alleles | |
| HLA class I expression | |
| HLA class II | |
| HLA class II-knockout | |
| HLA class-I | |
| HLA Crossmatch | |
| HLA diversity | |
| HLA DPB1* antibodies | |
| HLA DPB1* typing | |
| hla epitopes | |
| HLA expression | |
| HLA frequencies | |
| HLA frequency | |
| HLA genes | |
| HLA genotyping | |
| HLA haplotypes | |
| HLA homozygous donor | |
| HLA immunization | |
| HLA imputation | |
| HLA incompatible | |
| HLA loss relaps | |
| HLA loss relapse | |
| HLA matching | |
| HLA mismatch | |
| HLA mismatches | |
| HLA molecular diversity | |
| HLA Monoclonal Antibody | |
| HLA polymorphism | |
| HLA sensitization | |
| HLA serological specificities | |
| HLA staff | |
| HLA typing | |
| HLA-B | |
| HLA-B*35 | |
| HLA-B*35:435:02 | |
| HLA-C | |
| HLA-Containing Exosomes | |
| HLA-DM | |
| HLA-DM-meditated peptide editing | |
| HLA-DO | |
| HLA-DP | |
| HLA-DP immunopeptidome | |
| HLA-DPB1 | |
| HLA-DPB1 matching | |
| HLA-DQ | |
| HLA-DQA1 | |
| HLA-DQB1*02 | |
| HLA-DQB1*08 | |
| HLA-DR | |
| HLA-DR negative myeloid cells | |
| HLA-DRA | |
| HLA-DRB1 | |
| HLA-F | |
| HLA-G | |
| HLA-G polymorphisms | |
| HLA-H | |
| HLA-I alterations | |
| HLA-Matchmaker | |
| HLA-mediated drug hypersensitivity | |
| HLA-mismatch | |
| HLAMatchmaker | |
| HNA | |
| homozygosity | |
| hospitalization | |
| HPA | |
| hsa-miR-20a | |
| hsa-miR-92b | |
| HSC transplant | |
| HSCT | |
| HSCT - Hematopoietic Stem Cell Transplantation | |
| HSCT transplantation | |
| HSCT-Hematopoietic stem cell transplantation | |
| HSCT: Hematopoietic Stem Cell Transplantation | |
| Human | |
| Human and chimpanzee comparative genetics | |
| Human cytomegalovirus | |
| Human evolution | |
| Human Leucocyte Antigene H | |
| Human Leukocyte Antigen | |
| Human Neutrophil Antibodies | |
| Humoral immunity | |
| humoral rejection | |
| Hybrid capture | |
| Hypersensitivity reactions | |
| I | |
| IgG Subtypes | |
| IL-5 IL-9 and IL-13 genes | |
| Illumina | |
| ILT-2 | |
| imaging mass cytometry | |
| imatinib | |
| immune cell | |
| Immune cell profiling | |
| Immune Cells | |
| immune checkpoint | |
| Immune deficiency | |
| immune pathways | |
| immune reconstitution | |
| Immune repertoire | |
| Immune Thrombocytopenic Purpura | |
| Immune-mediated rejection | |
| Immunity | |
| immunochekpoints | |
| Immunoediting | |
| immunogenetics | |
| Immunogenetics population | |
| immunogenicity | |
| Immunogentics of SARS-CoV-2 | |
| immunoglobulin | |
| immunology | |
| Immunomodulation | |
| Immunopeptidome | |
| immunopeptidomes | |
| immunophenotyping | |
| Immunoprotection | |
| immunoregulation | |
| Immunosequencing | |
| immunosuppression | |
| immunotherapy | |
| Implementation | |
| Imputation | |
| Inclusiveness | |
| indel analysis | |
| induction immunosuppression | |
| induction therapy | |
| Infection | |
| Inflammatory bowel disease | |
| Influence | |
| Interspersed genomic repeats | |
| Intron sequences | |
| Invasive pneumococcal diseases (IPDs) | |
| iSeq | |
| Isolation T and B cells | |
| Israel | |
| ITP | |
| J | |
| Japanese | |
| Jon van Rood | |
| Journal | |
| Julia | |
| K | |
| Kell | |
| Kidney | |
| Kidney Transplant | |
| Kidney transplantation | |
| killer cell immunoglobulin-like receptor | |
| Killer Immunoglobulin-like Receptors (KIR) | |
| killer-cell immunoglobulin-like receptor | |
| killer-cell Immunoglobulin-like receptor (KIR) | |
| KIR | |
| KIR/HLA interactions | |
| KIR3DL1/S1 | |
| Knockout | |
| L | |
| Labscreen | |
| LAIR | |
| Landsteiner-Wiener | |
| Lecture | |
| Leukemia | |
| Lewis | |
| Ligands of NK cell receptors | |
| LILR | |
| LIMS | |
| Linkage disequilibrium | |
| Liquid Handler | |
| Liver | |
| Liver transplant | |
| long non coding RNA | |
| long short-term memory (LSTM) | |
| long-read sequencing | |
| Loss of Heterocigosity | |
| Loss of heterozigosity (LOH) | |
| Loss of heterozygosity | |
| LRC | |
| Luminex | |
| Luminex screening test | |
| Luminex Single Antigen (LSA) | |
| Luminex-beads | |
| lung transplant | |
| Lung transplantation | |
| Lymphocytes | |
| Lymphoma | |
| M | |
| Macaques | |
| machine learning | |
| Macrophages | |
| Magic | |
| Major histocompatibility complex | |
| Major histocompatibility complex (MHC) | |
| Matched Unrelated Haematopoietic Stem Cell Transplantation | |
| matched unrelated stem cell donor | |
| Matching | |
| Maternal-fetal interface | |
| MaxPrep | |
| Maxwell | |
| mean fluorescence intensity | |
| memory B cells | |
| menstrual blood | |
| menstrual cycle | |
| Mesenchymal Stem Cells | |
| Mesenchymal Stromal Cells | |
| Mesencyhmal Stem Cells | |
| Method development | |
| MFI | |
| MHC | |
| MHC class I A evolution | |
| MHC evolution | |
| MHC homozygous haplotype | |
| MHC-DQB | |
| MICA | |
| MICB | |
| microbiota | |
| Microfluidic | |
| microRNA | |
| MIF | |
| minimal typing requirements | |
| minor histocompatibility antigens | |
| minor histocomptibility antigens | |
| miRNA | |
| miRNA PCR array | |
| MiSeq | |
| Mismatched | |
| mismatches | |
| Monoclonal antibodies therapy | |
| monoclonal antibody | |
| monocytes | |
| Morocco | |
| Mortality | |
| mother-child pairs | |
| MPN | |
| MRI | |
| mTOR | |
| Multi-region | |
| Multiple sclerosis | |
| multiplex | |
| Multiplex based HLA typing | |
| Multiplex dPCR | |
| Multiplex NGS | |
| Myasthenia Gravis | |
| myeloid | |
| myeloproliferative neoplasms | |
| N | |
| Nanopore sequencing | |
| natural killer cell | |
| Natural Killer Cells | |
| Necrotizing myopathy | |
| neo-epitopes | |
| neurological disease | |
| Neuromyelitis optica | |
| New allele | |
| New Alleles | |
| New Technolgies | |
| next generation sequencing | |
| Next-Generation Sequencing | |
| NGS | |
| NGS based genotyping | |
| NGS long read | |
| NGS sequencing | |
| NGS typing | |
| NGS: Next Generation Sequencing | |
| NK alloreactivity | |
| NK cell | |
| NK cell receptors | |
| NK cells | |
| NKG2D | |
| Nodding Syndrome | |
| non classical HLAII | |
| non-classical HLA genes | |
| Non-HLA | |
| nonHLA | |
| North-West region of Russia | |
| Novel allele | |
| Novel Alleles | |
| NPM1 mutation A/D | |
| Nucleophosmin | |
| O | |
| oocyte donation | |
| Open Science | |
| Optimization | |
| organ allocation | |
| organ donor | |
| Organoids | |
| Outcome | |
| overal and cancer-specific survival | |
| Oxford Nanopore sequencing | |
| P | |
| PacBio | |
| Pacbio sequencing | |
| PacBio SMRT Sequencing | |
| Paediatric patients | |
| Paediatrics heart transplantation | |
| Pandemic | |
| pathway | |
| Patient outcome | |
| patient survival | |
| Patr genes | |
| PCR array | |
| PCR-SSP | |
| PD-L1 expression | |
| Pediatric disease | |
| pemphigus | |
| peptide binding motifs | |
| Peptide binding prediction | |
| Peptide editing | |
| peptide editor | |
| peptide repertoires | |
| peptide-binding groove polymorphism | |
| Permissible mismatch | |
| permissive mismatches | |
| Permissiveness | |
| permissiveness of HLA mismatch | |
| Personalized Immunotherapy | |
| personalized medicine | |
| Pharmacogenetics | |
| Phasing | |
| PIRCHE | |
| placenta | |
| placental pathology | |
| Plasma Exchange | |
| Platelet | |
| Polymorphism | |
| Population coverage | |
| Population Genetics | |
| Population reference graph (PRG) | |
| Population Study | |
| post hematopoietic stem cell transplantation | |
| Post-transplant antibodies | |
| Post-transplant lymphoproliferative disease (PTLD) | |
| Poster | |
| PRA (panel-reactive antibody) | |
| pre-existing tissue-resident memory | |
| pre-transplant risk assessment | |
| Prediction | |
| pregnancy | |
| primary tumors | |
| Primates | |
| PROCARE Consortium | |
| Profiling | |
| Promega | |
| Pronase | |
| Proteome | |
| psoriasis vulgaris | |
| psoriatic arthritis | |
| Q | |
| QIAcuity Digital PCR System | |
| R | |
| RAET1E | |
| Rare alleles | |
| rare allleles | |
| Rare disease | |
| RAS | |
| Reactive programming | |
| Real-time PCR | |
| receptors | |
| recombinant HLA | |
| Recurrent Pregnancy Loss | |
| Reference cell lines | |
| reference panel | |
| reflex beads | |
| Regenerative medicine | |
| REGULATION | |
| Regulatory B cells | |
| Regulatory T cells | |
| rejection | |
| related HLA identical donor | |
| Remarks | |
| renal | |
| Renal Transplantation | |
| Research evaluation | |
| Resolution of Ambiguities | |
| resolving not yet known sequences | |
| Rhesus macaques | |
| Rheumatoid Arthritis | |
| RNA-Seq | |
| Robotics | |
| RPL | |
| RPL with subsequent ongoing pregnancy | |
| S | |
| sacroiliitis | |
| Sample throughput | |
| sarcoma | |
| Sars-Cov | |
| SARS-CoV-2 | |
| SARS-CoV2 | |
| SARSCoV2 | |
| second transplantation | |
| sensitivity | |
| Sensitization | |
| Sensitized Patients | |
| sensitizing event | |
| sensitizing events | |
| Sequences | |
| Sequencing | |
| Session | |
| severity | |
| Shiny | |
| SHLARC | |
| short-read sequencing | |
| simulation | |
| Simultaneous Liver-Kidney Transplantation | |
| Single Antigen Bead Assay | |
| Single cell RNA sequencing | |
| Single Nucleotide Polymorphism | |
| Single Nucleotide Polymorphisms (SNPs) | |
| Single-cell RNA sequencing | |
| single-nucleotide polymorphism analysis | |
| SIRP | |
| Site-Directed Mutagenesis | |
| skin disease | |
| small-scale | |
| Software | |
| solid organ | |
| solid organ transplant | |
| Solid Organ Transplantation | |
| Solid-phase assays | |
| Soluble HLA | |
| Soluble HLA-G | |
| Somatic mutations | |
| splice site mutation | |
| Statistics | |
| Stem cell | |
| Stem Cell Registry | |
| Stem cell transplantation | |
| STR | |
| Stromal reaction | |
| structural variation | |
| Survey | |
| Survival | |
| Survival Analysis | |
| synovitis | |
| T | |
| T Cell | |
| T cell epitopes | |
| T cell receptor | |
| t cell rejection | |
| T cell responses | |
| T cells | |
| T-cell | |
| T-cell alloreactivity | |
| T-cell cross-reactivity | |
| T-cell epitopes | |
| T-cell receptor (TCR) repertoire | |
| T-Memory | |
| T-naive | |
| T1D | |
| TCE algorithm | |
| TCR repertoire analysis | |
| TCR: T Cell Receptor | |
| telomerase reverse transcriptase (TERT) | |
| telomere length | |
| TERT polymorphic variants | |
| TGS | |
| Th2 cytokine polymorphisms | |
| THP-1 | |
| Thymus | |
| tissue chimerism | |
| TNFA | |
| tocilizumab | |
| Tolerance | |
| transcription factor | |
| transcytosis | |
| transfusion | |
| Transplant | |
| Transplant algorithm | |
| Transplant vasculopathy | |
| transplant-reated mortality | |
| Transplantability score | |
| Transplantation | |
| Transposable elements | |
| Treg | |
| trophoblast | |
| Trophoblast interactions | |
| tumor grade | |
| tumor microenvironment | |
| Tumor-Associated Antigens | |
| tumor-derived exosomes | |
| Turn around time | |
| type 1 diabetes mellitus | |
| Type-1-Diabetes Mellitus | |
| typing | |
| U | |
| ULBP4 | |
| UMAP | |
| Umbilical Cord Blood | |
| Umbilical Cord Tissue (Wharton’s Jelly) | |
| undifferentiated spondyloarthritis | |
| unrelated donor | |
| Unrelated donors | |
| Unrelated Haematopoietic Stem Cell Transplantation | |
| V | |
| Vaccination | |
| Vaccine | |
| Varicella zoster virus | |
| VDR polymorphism | |
| Vel | |
| very rare alleles | |
| W | |
| waiting list | |
| Waiting lists | |
| Website | |
| Welcome | |
| Well Defined alleles | |
| Whole exome sequencing | |
| Whole genome sequence | |
| Whole genome sequencing | |
| Work flow assessment | |
| Workflows | |
| X | |
| Xenotransplantation | |
| α | |
| αβ T cells | |
| γ | |
| γδ T cells | |
| γδT cells | |